Israeli scientists from Technion have discovered a genetic 'fingerprint' that may predict a patient's response to immunotherapy. This breakthrough could greatly improve personalized cancer treatments by identifying who will benefit most. Immunotherapy boosts the immune system's ability to target cancer, and this finding may enhance its effectiveness and precision.